[{"Assets_0_Q2_USD":56500000.0,"CommonStockSharesOutstanding_0_Q2_shares":38640487.0,"EarningsPerShareBasic_1_Q2_USD":-0.24,"EarningsPerShareBasic_2_Q2_USD":-0.49,"EarningsPerShareDiluted_1_Q2_USD":-0.24,"EarningsPerShareDiluted_2_Q2_USD":-0.49,"NetIncomeLoss_1_Q2_USD":-9100000.0,"NetIncomeLoss_2_Q2_USD":-19100000.0,"StockholdersEquity_0_Q2_USD":28000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":38640487.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":38640487.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":38640487.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":38640487.0,"Ticker":"VXRT","CIK":"72444","name":"AVIRAGEN THERAPEUTICS, INC.","OfficialName":"Vaxart Inc Common Stock","form":"10-Q","period":"20161231","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"564888665.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20170206"}]